mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic

The advent of mRNA vaccines represents a significant advance in the field of vaccinology. While several vaccine approaches (mRNA, DNA, recombinant protein, and viral-vectored vaccines) had been investigated at the start of the COVID-19 pandemic, mRNA vaccines quickly gained popularity due to superio...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 14; p. 1155728
Main Authors Xu, Ziyang, Fisher, David E
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 30.03.2023
Subjects
Antibodies, Neutralizing
Antibodies, Viral
cancer vaccination
COVID – 19
COVID-19 - prevention & control
COVID-19 Vaccines
Humans
Immunology
Melanoma
mRNA vaccination
neoantigen
Pandemics - prevention & control
RNA, Messenger - genetics
SARS-CoV-2
Viral Vaccines
neoantigen
melanoma
cancer vaccination
COVID – 19
mRNA vaccination
Online AccessGet full text

Cover

More Information
Summary:The advent of mRNA vaccines represents a significant advance in the field of vaccinology. While several vaccine approaches (mRNA, DNA, recombinant protein, and viral-vectored vaccines) had been investigated at the start of the COVID-19 pandemic, mRNA vaccines quickly gained popularity due to superior immunogenicity at a low dose, strong safety/tolerability profiles, and the possibility of rapid vaccine mass manufacturing and deployment to rural regions. In addition to inducing protective neutralizing antibody responses, mRNA vaccines can also elicit high-magnitude cytotoxic T-cell responses comparable to natural viral infections; thereby, drawing significant interest from cancer immunotherapy experts. This mini-review will highlight key developmental milestones and lessons we have learned from mRNA vaccines during the COVID-19 pandemic, with a specific emphasis on clinical trial data gathered so far for mRNA vaccines against melanoma and other forms of cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
Edited by: Ramesh Akkina, Colorado State University, United States
Reviewed by: Vladimir Alexeevich Gushchin, Russian Academy of Medical Sciences, Russia
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1155728